MYL

Mylan N.V.

Healthcare


Presented:04/18/2018
Price:$40.74
Cap:$21.82B
Current Price:$11.84
Cap:$14.13B

Presented

Date04/18/2018
Price$40.74
Market Cap$21.82B
Ent Value$36.82B
P/E Ratio31.58x
Book Value$25.39
Div Yield0%
Shares O/S535.70M
Ave Daily Vol4,881,274
Short Int5.10%

Current

Price$11.84
Market Cap$14.13B
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.

Please note, this is an update to Mylan NV (MYL) - Long, which was presented on 10/30/2017

Publicly traded companies mentioned herein: Mylan Nv (MYL), Teva Pharmaceutical Industries (TEVA)

Highlights

The presenter is long shares of Mylan (MYL), viewing the stock as sufficiently de-risked given its cheap valuation. MYL has been categorized by investors as an underperforming large cap pharma company whose business is tied to US generics. However, he thinks this perception is incorrect, as MYL has demonstrated a reasonable ability to grow earnings and hit long-term guidance targets. MYL’s pipeline could yield a stream of potential approvals over the coming years, and he models $5.40 and $6.00 in 2018 and 2019 EPS, respectively. A $60 price target based on an ~11x – 12x P/E multiple seems fair.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.